Reportstack is one of the largest online libraries of market research publications. We are the fastest growing and most preferred provider of business intelligence in the market today. We partner with the world's top publishers and research houses to bring to you expert analysis, accurate data and market information along with the best customer support and user experience. For more details, please visit www.reportstack.com
Tuesday, 18 April 2017
Detailed Study of the Global Ulcerative Colitis Drug Market 2025
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 is a new market research publication announced by Reportstack. Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of the colon and rectum. As a result, the colon's ability to absorb water is decreased, which leads to progressive loosening of the stool, bloody stool, and sometimes cramping or abdominal pain, with urgency for bowel movement. Other associated symptoms of UC include loss of appetite, weight loss, fatigue, and anaemia in cases of severe bleeding. The exact causes or triggers of the disease are yet to be identified; however, it is known that in people with UC, the body's immune system mistakes bacteria, food, and other materials in the intestine for foreign substances and attacks the colon tissues, leading to chronic inflammation of the colon linings. UC is a relapsing, remitting chronic disease that requires life long medical management and patients. Attributing to unknown aetiology of UC, all current pharmacopoeia provide immunosuppressive, symptomatic relief, as no curative disease therapy is available yet. Based on disease location and severity, patients receive different treatment alternatives either for induction or maintenance of remission.
- The newly launched anti-integrin antibody Entyvio and Remicade biosimilars, will see an increase in patient shares for the treatment of severe UC. Will these newly marketed make a significant impact on the UC market? Which of these drugs will have the highest peak sales at the highest CAGR, and why? - The most notable candidate in the current late-stage UC pipeline is new generation ozanimod hydrochloride and Xeljanz (tofacitinib), which are predicted to have a notable impact in the moderate to severe UC space over this forecast period. However, there are still considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the UC market? - We have seen a notable increase in the UC population in terms of diagnosed prevalent UC cases for mild to moderate and moderate to severe disease. How will epidemiological changes impact the growth of the future market?
- The main driver for the UC market will be the launch of Celgene’s first-in-class Sphingosine 1 Phosphate Receptor 1 (S1P1) modulator, ozanimod hydrochloride, in all 6MM. Launch of Pfizer’s Xeljanz, Johnson and Johnson’s Stelara (ustekinumab), Lipid Therapeutics’ LT-02, and Roche’s etrolizumab will also contribute to global UC market growth. - The major global barrier for the UC market will be the sales erosion of blockbuster biologic drugs for moderate to severe UC space due to launch and increasing use of anti-tumor necrosis factor (TNF) biosimilars over this forecast period. - In the future, the dynamics of the lucrative moderate to severe UC market will shift greatly from the historical strategy of developing biologic drugs, towards small molecule oral drugs. - The key market opportunities lie in addressing unmet needs through the development of oral agents with superior efficacy and safety profile, low cost, curative UC therapy as well as drugs that help minimise colorectal cancer risk.
- Overview of UC, including epidemiology, aetiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global UC therapeutics market from 2015-2025. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Johnson & Johnson (J&J) AbbVie Takeda Pharmaceuticals Salix Pharmaceuticals Pfizer Inc. F. Hoffmann-La Roche Ltd. InDex Pharmaceuticals Lipid Therapeutics GmbH Celgene Corporation EA Pharma Ferring International Tillotts Pharma